Researchers report a cleaner living environment may not detrimentally impact a child's developing immune system, as current theories suggest.
Narratives and storytelling can help counter vaccine misinformation as the method can create a bridge between scientific evidence and human experience.
A number of videos have surfaced on popular channels showing people experiencing some adverse effects following the coronavirus vaccine. Researchers say some of the cases could be related to functional neurological disorder, a common neuropsychological condition.
Researchers have carried out clinical trials to test a mutation-specific vaccine against malignant brain tumors. The vaccine has been found to be safe and effective in triggering the desired immune response in the brain cancer tumors.
When injected with the new mRNA vaccine, mice with multiple sclerosis-like symptoms developed less severe symptoms than would normally occur.
A newly developed experimental vaccine can diminish the fatal respiratory effects of carfentanil and fentanyl in rodent models.
By adding a molecule that disrupts certain pathways in cells, researchers have discovered a new way to limit inflammation from adjuvants in vaccinations.
Using computational methods, researchers created artificial proteins that triggered immune responses and produced infection specific antibodies. The findings indicate it will be possible to design vaccines that contain artificial antibodies, expediting the process of vaccine development.
Researchers report they have identified a vaccine candidate for COVID-19 and are working towards phase one clinical testing. A chimpanzee adenovirus vaccine vector was chosen as the most suitable vaccine technology for SARS-CoV-2 as it can generate a stronger immune response in one dose and is not a replicating virus.
Researchers are making progress in developing potential vaccines for coronavirus infections. While a vaccine for COVID-19 might be over a year away from market, researchers are looking ahead to attempt to prevent future outbreaks.
Clinical trials for a preventative treatment for dementia was successful in mouse models. Researchers say human trials will begin in two years.
A newly developed vaccine for meningitis and other bloodstream infections caused by the meningococcal group B bacteria will allow for the immunization of younger children. The new vaccine also addresses several limitations of the current meningitis vaccine.
